Boston Scientific and The Medicines Company Announce U.S. Co-Promotion Agreement for Promus PREMIER™ Stent System
NATICK, Mass. and PARSIPPANY, N.J., Dec. 6, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and The Medicines Company (NASDAQ: MDCO) announce a co-promotion agreement for the Boston Scientific Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System. Under the terms of the agreement, The Medicines Company's acute cardiovascular care sales force will collaborate with the Boston Scientific Interventional Cardiology sales force to provide promotional support for the Promus PREMIER Stent System in U.S. hospitals beginning January 1, 2014.
The Promus PREMIER Stent System, the latest Boston Scientific FDA-approved drug-eluting stent (DES), offers physicians improved performance in treating patients with coronary artery disease. It features a unique, customized platinum chromium alloy stent architecture, combined with the market-leading Everolimus drug, a biocompatible, fluorinated co-polymer, and an enhanced stent delivery system. Coronary artery disease is a narrowing of blood vessels that supply blood and oxygen to the heart. Patients with coronary artery disease may experience chest pain, shortness of breath and fatigue, and may also be at risk for a heart attack. One established treatment option is the placement of a stent in the artery to help keep it open and allow the blood to flow more freely.
"The Medicines Company's established and highly complementary product portfolio in interventional cardiology will enhance the capabilities of our sales force as we introduce the Promus PREMIER System in the U.S. market," said Matt Franklin, vice president, Interventional Cardiology Global Marketing, Boston Scientific. "This collaborative agreement brings together two of the market leading providers of interventional cardiology and acute care solutions to better support our customers and the patients they serve."
"Our goal in entering into this agreement with Boston Scientific is to help improve patient care with a comprehensive suite of solutions for acute cardiovascular care," said Brent Furse, senior vice president and chief customer officer of The Medicines Company. "This intensifies our efforts to save lives, alleviate suffering and contribute to the economics of healthcare by serving leading hospitals."
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
About The Medicines Company
The Medicines Company's purpose is to save lives, alleviate suffering, and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.
Boston Scientific Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding product performance, the impact of the co-promotion agreement and our business plans. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
The Medicines Company Forward Looking Statements
Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "plans, "anticipates" and "expects" and similar expressions, including the Company's preliminary revenue results, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include whether the Company will make regulatory submissions for product candidates on a timely basis, whether its regulatory submissions will receive approvals from regulatory agencies on a timely basis or at all, whether physicians, patients and other key decision makers will accept clinical trial results, and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Registration Statement on Form 10-Q filed on November 5, 2013, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.
Boston Scientific Contacts:
Global Media Relations
Boston Scientific Corporation
Susan Vissers Lisa, CFA
Boston Scientific Corporation
The Medicines Company Contacts:
Neera Dahiya Ravindran, MD
Vice President, Investor Relations & Strategic Planning
The Medicines Company
+1 (973) 290-6044
Senior Director, Investor Relations & Communications
The Medicines Company
+1 (973) 290-6097
SOURCE Boston Scientific Corporation